Ku ya 27 Nzeri, urubuga rwemewe rwa CDE rwerekanye ko gusaba kwerekana ibimenyetso bishya bya cream ya Pfize Crisaborole (izina ry'ubucuruzi mu Bushinwa: Sultanming, izina ry'ubucuruzi bw'icyongereza: Eucris a, Staquis) byemewe, bishoboka ko ari abana ndetse n'abantu bakuru bafite amezi 3 kandi abarwayi ba atopic dermatitis bakuze.

Crisaborole ni molekile ntoya, idafite imisemburo, nonsteroidal anti-inflammatory topical phosphodiesterase 4 (PDE-4) inhibitor yakozwe na Anacor.Muri Gicurasi 2016, Pfizer yaguze isosiyete miliyoni 5.2 z'amadolari maze agura ibiyobyabwenge.Mu Kuboza k'uwo mwaka, Crisaborole yemejwe na FDA yo kwamamaza, ibaye imiti ya mbere yandikiwe na dermatite ya atopic yemejwe mu myaka 10, ndetse n'umuti wa mbere utari steroidal wo hanze wabuza uruhu PDE4.

Inzitizi ya Crisaborole nk'umuti mushya, mubyukuri, impapuro zo mu kanwa zakoreshejwe kuri plaque psoriasis itagabanije kandi ikabije na arthritis ya psoriatic, ingaruka nyamukuru ni ukutagira igifu, nta yandi mabara yihariye.

Crisaborole nk'imiti yibanze, idakoreshwa cyane muruhu, amahirwe yiyi ngaruka mbi yo kutagira gastrointestinal nayo aragabanuka kugeza hasi cyane.

Kubera iyo mpamvu, Crisaborole yahise ahinduka "ibyiringiro byumudugudu wose" kuva mu myaka 15, abaganga nababyeyi bashishikajwe no gukoresha neza, neza kandi igihe kirekire gukoresha imiti yibanze ni ndende cyane.

Ibiyobyabwenge bifite akamaro kangana iki na Crisaborole?

Mu mwaka wa 2016, ubushakashatsi bubiri bwo mu cyiciro cya gatatu cy’amavuriro bwazanye amakuru ashimishije cyane, Crisaborole, amavuta y’ibanze ya inhibitori ya fosifisiyose-4 (PDE4), ku barwayi barwaye dermatite ya Atopic barengeje imyaka 2 (abana n’abakuze), bageze ku mavuriro meza.